Shanghai-based rare disease specialist Linno Pharmaceuticals Inc. has reportedly raised close to RMB 100 million (USD 14.78 million) in angel and pre-Series A financing rounds. The round was led by Puhua Capital, with contributions from Zhangke Lingyi Investment.
Funding Use
Proceeds will support upgrades in blood-brain barrier-crossing macromolecular drug delivery technology and the development of new drugs based on complement inhibition.
Company Profile
Founded in 2019, Linno Pharma has proprietary technology platforms for developing protein drugs capable of crossing the blood-brain barrier. A recombinase replacement therapy for metachromatic leukoencephalopathy (MLD) is expected to enter clinical trials within two years. Additionally, a novel complement antibody for IgA nephropathy is being prepared for IND filing.-Fineline Info & Tech
